Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

被引:25
|
作者
Fujimoto, Yukie [1 ]
Watanabe, Takahiro [2 ]
Hida, Akira I. [3 ]
Higuchi, Tomoko [1 ]
Miyagawa, Yoshimasa [1 ]
Ozawa, Hiromi [1 ]
Bun, Ayako [1 ]
Fukui, Reiko [1 ]
Sata, Atsushi [1 ]
Imamura, Michiko [1 ]
Hirota, Seiichi [2 ]
Miyoshi, Yasuo [1 ]
机构
[1] Hyogo Coll Med, Dept Surg, Div Breast & Endocrine Surg, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Dept Surg Pathol, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[3] Matsuyama Shimin Hosp, Dept Pathol, 2-6-5 Otemachi, Matsuyama, Ehime 7900067, Japan
关键词
Breast cancer; Tumor-infiltrating lymphocytes; Ki67; Prognosis; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; HIGHLIGHTS; CHEMOTHERAPY; SUBTYPES;
D O I
10.1007/s12282-019-00977-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been established in breast cancers with estrogen receptor (ER)-negative and human epithelial growth factor receptor 2 (HER2)-negative or HER2-positive subtypes; however, its utility concerning the ER + /HER2-subtype remains unclear. Methods We evaluated the prognostic value of TILs by analyzing 717 invasive breast cancer operation cases. TILs were classified into three groups based on the proportion of area within the tumor: low (< 10%), intermediate (10-50%), and high (> 50%). Disease-free survival (DFS) and overall survival (OS) were calculated according to TIL levels. Results Although there was no significant association between TIL levels and DFS or OS in all patients, high TILs were significantly associated with favorable DFS in Ki67-high (n = 238, p = 0.035) but not in Ki67-low (n = 470, p = 0.46) breast cancers. Multivariable analysis showed that high TILs were a significant and independent factor for DFS (HR 0.34; 95% CI 0.10-0.87; p = 0.023) among the Ki67-high group. In the ER + /HER2 - subtype, high-TILs showed favorable DFS in the Ki67-high group, although this was not statistically significant (p = 0.48); in contrast, unfavorable DFS was observed in the Ki67-low group (p = 0.027). Conclusions In Ki67-high breast cancers, high TILs were associated with favorable DFS, irrespective of subtype, but increasing TIL levels correlated with worse DFS in the Ki67-low group with the ER + /HER2 -subtype. These results highlight variation in TIL prognostic significance between Ki67-high and -low breast cancers, particularly for the ER + /HER2 - subtype.
引用
收藏
页码:738 / 747
页数:10
相关论文
共 50 条
  • [21] Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
    Nederlof, I
    Hajizadeh, S.
    Sobhani, F.
    Raza, S. E. A.
    AbdulJabbar, K.
    Harkes, R.
    van de Vijver, M. J.
    Salgado, R.
    Desmedt, C.
    Kok, M.
    Yuan, Y.
    Horlings, H. M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [22] Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index
    Ono, Makiko
    Tsuda, Hitoshi
    Yoshida, Masayuki
    Shimizu, Chikako
    Kinoshita, Takayuki
    Tamura, Kenji
    CLINICAL BREAST CANCER, 2017, 17 (01) : 41 - 47
  • [23] Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers
    Murase, Keiko
    Yanai, Ayako
    Saito, Masaru
    Imamura, Michiko
    Miyagawa, Yoshimasa
    Takatsuka, Yuichi
    Inoue, Natsuko
    Ito, Takashi
    Hirota, Seiichi
    Sasa, Mitsunori
    Katagiri, Toyomasa
    Fujimoto, Yasuhisa
    Hatada, Takuya
    Ichii, Shigetoshi
    Nishizaki, Tomoyuki
    Tomita, Naohiro
    Miyoshi, Yasuo
    BREAST CANCER, 2014, 21 (01) : 52 - 57
  • [24] High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer
    Nishimukai, Arisa
    Yagi, Tomoko
    Yanai, Ayako
    Miyagawa, Yoshimasa
    Enomoto, Yukie
    Murase, Keiko
    Imamura, Michiko
    Takatsuka, Yuichi
    Sakita, Isao
    Hatada, Takuya
    Miyoshi, Yasuo
    CLINICAL BREAST CANCER, 2015, 15 (03) : 204 - 211
  • [25] Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers
    Kaolu Sato
    Minoru Miyashita
    Takanori Ishida
    Akihiko Suzuki
    Hiroshi Tada
    Go Watanabe
    Akiko Sato-Tadano
    Mika Watanabe
    Noriaki Ohuchi
    Breast Cancer, 2016, 23 : 310 - 317
  • [26] Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
    Kurozumi, Sasagu
    Matsumoto, Hiroshi
    Hayashi, Yuji
    Tozuka, Katsunori
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Kurosumi, Masafumi
    BMC CANCER, 2017, 17
  • [27] Correlation between magnetic resonance imaging and the level of tumor-infiltrating lymphocytes in patients with estrogen receptor-negative HER2-positive breast cancer
    Choi, Woo Jung
    Kim, Youyeon
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Yoon, Ga Young
    Kim, Hak Hee
    ACTA RADIOLOGICA, 2020, 61 (01) : 3 - 10
  • [28] Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers
    Keiko Murase
    Ayako Yanai
    Masaru Saito
    Michiko Imamura
    Yoshimasa Miyagawa
    Yuichi Takatsuka
    Natsuko Inoue
    Takashi Ito
    Seiichi Hirota
    Mitsunori Sasa
    Toyomasa Katagiri
    Yasuhisa Fujimoto
    Takuya Hatada
    Shigetoshi Ichii
    Tomoyuki Nishizaki
    Naohiro Tomita
    Yasuo Miyoshi
    Breast Cancer, 2014, 21 : 52 - 57
  • [29] Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
    Hida, Akira I.
    Sagara, Yasuaki
    Yotsumoto, Daisuke
    Kanemitsu, Shuichi
    Kawano, Junko
    Baba, Shinichi
    Rai, Yoshiaki
    Oshiro, Yumi
    Aogi, Kenjiro
    Sagara, Yoshiaki
    Ohi, Yasuyo
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 1 - 9
  • [30] Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy
    Montagna, Emilia
    Vingiani, Andrea
    Maisonneuve, Patrick
    Cancello, Giuseppe
    Contaldo, Federica
    Pruneri, Giancarlo
    Colleoni, Marco
    BREAST, 2017, 34 : 83 - 88